PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1697828
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1697828
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
Scope of the Report | |
---|---|
Years Considered for the Study | 2023-2030 |
Base Year | 2024 |
Forecast Period | 2025-2030 |
Units Considered | Value (USD) |
Segments | By Products & Service, Application and End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"Instruments dominated the products & service segment"
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
"Drug discovery & development application segment is anticipated to grow at a great pace"
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
"Pharmaceutical & Biotechnology Companies dominated the segment"
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
"North America: the largest share of the high content screening market"
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country's focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Corning Incorporated (US), Bio-Rad Laboratories Inc (US), Tecan Trading AG (Switzerland), Evident (Japan), Sysmex Corporation (Japan), Yokogawa Electric Corporation (Japan), Nikon Corporation (Japan), Sartorius AG (Germany), Promega Corporation (US), Creative Biolabs (US), Enzo Life Sciences (US), Stratedigm Inc. (US), Akoya Biosciences, Inc. (US), Sphere Fluidics (UK), Creative Biostructure (US), Creative Bioarray (US), Cell Signalling Technology (US), Standard Biotools (US), Araceli Biosciences (US), and among others.
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.